In March, Shanghai Junshi Biosciences Co Ltd announced collaboration with Singapore-based Rxilient Biotech on development and commercialization of an antibody drug through a joint venture in nine Southeast Asian nations — Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.
今年3月，上海君实生物科技有限公司宣布，通过在泰国、文莱、柬埔寨、印度尼西亚、老挝、马来西亚、缅甸、菲律宾和越南等九个东南亚国家的合资企业，与新加坡的Rxilent Biotech合作开发抗体药物并将其商业化。
"The company said it is planning to launch the antibody drug in more markets.
该公司表示，计划在更多市场推出这种抗体药物。
Toripalimab is also the only anti-PD-1 monoclonal antibody included in the list for the treatment of melanoma.
托里帕利单抗也是唯一一种被列入黑色素瘤治疗名单的抗PD-1单克隆抗体。
Loqtorzi is the first US FDA-approved agent for NPC patients, and is a next-generation, programmed death receptor-1 monoclonal antibody, commonly known as PD-1 antibody.
Loqtorzi是美国食品药品监督管理局批准的第一种用于NPC患者的药物，是下一代程序性死亡受体-1单克隆抗体，通常被称为PD-1抗体。
"The approval of the homegrown antibody is the first of its kind for treating NPC in the US, and that's a milestone for China's innovative medicine industry," said Xu Ruihua, president of Sun Yat-sen University Cancer Center, and the principal investigator of the drug.
“国产抗体的批准是美国首例用于治疗NPC的抗体，这对中国创新医药行业来说是一个里程碑，”该药物的首席研究员、中山大学癌症中心院长徐瑞华说。
In March of this year, Sino Biopharmaceutical successfully acquired F-star, which is an internationally leading biotechnology company in the research and development of dual antibody platforms.
今年3月，Sino Biopharmaceutical成功收购了F-star，这是一家在双抗体平台研发方面处于国际领先地位的生物技术公司。
The company has also established strategic partnerships with various China-based biotech and tech companies such as Innovent Biologic, Insilico Medicine, Adagene and Baidu, to accelerate its pace in fields including oncology, AI drug discovery and antibody development technology.
该公司还与Innovent Biologic、Insilico Medicine、Adagene和百度等多家中国生物技术公司建立了战略合作伙伴关系，以加快其在肿瘤学、人工智能药物发现和抗体开发技术等领域的步伐。
Zhu Jingjin, vice-president of China National Biotec Group－Sinopharm's biotech subsidiary－said three virus antibody drugs for COVID-19 have all entered clinical trials with steady progress.
中国国药集团生物技术子公司中国生物技术集团副总裁朱晶晶表示，三种治疗新冠肺炎的病毒抗体药物均已进入临床试验，并取得稳步进展。
Zhu Jingjin, deputy president of China National Biotec Group, China National Pharmaceutical Group's biotech subsidiary, said at a media conference in Beijing on Monday the company's three virus neutralizing antibody drugs for treating COVID-19 have all entered clinical trials and are showing steady progress.
中国医药集团旗下生物技术子公司中国生物技术集团副总裁朱晶晶周一在北京举行的媒体会议上表示，该公司用于治疗新冠肺炎的三种病毒中和抗体药物均已进入临床试验，并显示出稳步进展。
AstraZeneca announced Thursday during the 2022 Taihu Bay Future Healthcare Conference that it has formed a strategic partnership with WuXi Biologics on the local production of Evusheld, a long-acting antibody combination used for the pre-exposure prophylaxis of COVID-19.
阿斯利康周四在2022太湖湾未来医疗保健大会上宣布，它已与无锡生物制品公司就Evusheld的本地生产建立战略合作伙伴关系，Evusheld是一种用于新冠肺炎暴露前预防的长效抗体组合。
AstraZeneca's long-acting antibody combination was authorized for emergency use for pre-exposure prophylaxis of COVID-19 in the US in December 2021.
2021年12月，阿斯利康的长效抗体组合被授权在美国紧急用于新冠肺炎暴露前预防。
We are delighted to work with AstraZeneca to produce the long-acting antibody combination in China and help provide a stable supply of this product.
我们很高兴能与阿斯利康合作，在中国生产长效抗体组合，并帮助提供该产品的稳定供应。
"Adagene's antibody platform is expected to help us precisely target established, but poorly addressed oncology mechanisms with best-in-class medicines," she said.
她说：“Adagene的抗体平台有望帮助我们用一流的药物准确靶向已建立但解决不力的肿瘤机制。”。
Luo said the proprietary technology is a precision antibody masking platform designed to enable the antibody to bind to its target specifically only after conditional activation of the antibody in target tissues.
罗说，这项专有技术是一种精确的抗体掩蔽平台，旨在使抗体只有在靶组织中有条件激活抗体后才能特异性地与靶结合。
By engineering and developing therapeutic antibody candidates to selectively activate in the tumor microenvironment, the platform is designed to improve safety and tolerability of antibody therapeutics while maintaining clinical activity.
通过设计和开发治疗性候选抗体以在肿瘤微环境中选择性激活，该平台旨在提高抗体治疗的安全性和耐受性，同时保持临床活性。
Zai Lab, a Shanghai-based biopharmaceutical company, and its partner Argenx SE, a Europe-based immunology company, jointly announced that the United States Food and Drug Administration has approved Vyvgart for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.
上海生物制药公司Zai Lab及其合作伙伴欧洲免疫学公司Argenx SE联合宣布，美国食品和药物管理局已批准Vyvgart用于治疗抗乙酰胆碱受体抗体阳性的成人全身性重症肌无力。
Under the agreement, Boehringer Ingelheim Biopharma, a division of the German pharmaceutical company, will provide process optimization and clinical material manufacturing for the latter's bispecific antibody drug for potential treatment of COVID-19.
根据协议，德国制药公司旗下的勃林格殷格翰生物制药公司将为后者的双特异性抗体药物提供工艺优化和临床材料制造，用于潜在的新冠肺炎治疗。
GlaxoSmithKline is showcasing Mepolizumab, the world's first interleukin-5 monoclonal antibody, which has received approval in several countries, including the United States, for treatment on patients with inflammatory diseases caused by the presence of an abnormally increased number of eosinophils in the blood.
葛兰素史克公司正在展示世界上第一种白细胞介素-5单克隆抗体Mepolizumab，该抗体已在包括美国在内的几个国家获得批准，用于治疗因血液中嗜酸性粒细胞数量异常增加而引起的炎症性疾病患者。
The company's more than 10 innovative molecules in discovery, with focus on innate immunity and tumor microenvironment, competed with an innovative antibody drug treating tumors.
Yet if a person gets a third additional shot six months after he or she finishes the two-shot inoculation program, his or her antibody levels will increase five to 10 times, Chen said.
The milestone payment was triggered by the inoculations of the first two patients in the Phase-1/2 clinical trial of its SHP2 inhibitor JAB-3312 in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib, respectively.
Chinese biotech company BeiGene Ltd announced on Thursday the approval from the China National Medical Products Administration to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its biologics facility in Guangzhou, Guangdong province.
In December 2020, the Company and Utrecht University jointly announced a deal to out-license the global rights of development and commercialization for a fully human antibody ABBV-47D11 (HBM9022) to United States-based biopharmaceutical company AbbVie and authorized it to initiate clinical trials.
At the beginning of last year, BeiGene worked with United Kingdom-based biopharmaceutical company EUSA Pharma to introduce a monoclonal antibody drug for neuroblastoma for Chinese patients.
With the introduction of the monoclonal antibody drug, neuroblastoma patients are able to get medical treatment, bringing a chance of survival and cure for them.
In 2018, the NMPA included BeiGene's monoclonal antibody drug for neuroblastoma into the first batch of drugs on its badly as an imported drug for the clinical use catalog.
Its second drug at commercial stage, the anti-PD-1 antibody tislelizumab, also proved to be a success targeting at both domestic and global markets.
The fourth plant will mainly research, develop and produce anti-tumor monoclonal antibody and related cancer drugs independently, said Wang Xiaodong，founder of BeiGene and a foreign associate of Chinese Academy of Science, at the commencement ceremony.
Biotech company BeiGene Ltd announced Thursday its anti-PD-1 antibody tislelizumab has received approval from the country's National Medical Products Administration for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer.
At the booth of Eli Lilly, the US company and its Chinese partners from academia, hospitals and industry discussed the latest development of their joint efforts regarding clinical trials of two COVID-19-related antibody treatments and a marketed JAK inhibitor to treat complications of COVID-19.
Promising preclinical and preliminary Phase 1 data – which will be published in a peer-reviewed publication in the near future - indicate that S-Trimer is well-tolerated and produces strong neutralizing antibody and Th1-biased cell-mediated immune responses, which merit ongoing evaluation of the vaccine candidate, Clover said in a press release.
Recent instances include Amgen signing a global collaboration for oncology drug development with BeiGene, and Lilly licensing a neutralizing antibody asset for COVID-19 from Junshi Biosciences.
Lemzoparlimab, also known as TJC4, is an anti-CD47 monoclonal antibody discovered by the Shanghai-based company to treat multiple forms of cancer.
Zhang Yang, founder and CEO of ZXBio Co Ltd, has bold visions for his antibody production business in China.
"With an initial investment of 13 million yuan, ZXBio has developed more than 50 flow cytometry antibody diagnostic products, which unique surface substances－antigens－to assist physicians more precisely diagnose patients with complicated diseases, such as autoimmune disease, cancer, and coronavirus infection.
It allows the customization of antibody manufacturing based on market needs.
As a new entrant of the antibody diagnostic industry, Zhang plans to further tap the growing demand for diverse antibody diagnostic reagents with a novel manufacturing facility.
The world's first inactivated vaccine has shown a 100 percent antibody positive conversion rate, with all subjects producing antibodies according to the latest clinical results from its producer.
In the 18-to-59-year-old age group, those who got two doses of vaccine based on the 0-and-28-day procedure demonstrated 100 percent antibody positive conversion rate, while those who got two doses based on the 0-and-14-day procedure and 0-and-21-day procedure showed a 97.6 percent antibody positive conversion rate.
Upon arrival in China, they will need to take another COVID-19 and antibody test, and have to undergo a mandatory quarantine for 48 hours in Shanghai.
Chinese medical device company Guangzhou Wondfo Biotech Co Ltd said in an official statement on Tuesday that its SARS-CoV-2 antibody testing kits exported overseas met the quality requirements of China's National Medical Products Administration and countries that they were exported to, and vowed to proactively provide product training to medical staff in each country to ensure the proper use of the test.
The statement came after British media outlets reported that Wondfo's SARS-CoV-2 antibody testing kits exported to the United Kingdom were unqualified and didn't work out very well, and that the testing kits might need a month of trial period before being used.
As stated in the product description, the company's antibody test is for rapid, qualitative detection of the SARS-CoV-2 IgG/IgM antibody in a human whole blood, serum or plasma sample.
Later on, when the human body begins to produce specific antibodies through the immune response, the sensitivity and detection rate of an antibody testing kit could rise to a high level, he said.
"Therefore, for infected cases who have gone through the window period, using antibody testing as a supplementary testing method effectively raises the detection rate," Li added.
Wondfo said that between March 9 and Sunday, it had delivered millions of SARS-CoV-2 antibody testing kits to more than 70 countries and regions worldwide.
Thanks to much-improved research and development capabilities, Chinese companies were able to develop nucleic acid test kits quickly in January, soon after Chinese scientists published the genomic sequence of the virus, and then developed antibody tests later in February.
The National Medical Products Administration said it had approved 11 nucleic acid test kits and eight antibody test kits as of March 17.
And Jiangsu Medomics Medical Technology Co Ltd gave away 10,000 antibody test kits.
"Guangzhou Wondfo Biotech Co Ltd, a POCT (point-of-care testing) leader in China, announced on March 6 that its three newly developed SARS-CoV-2 antibody tests had received CE marking.
The Wondfo SARS-CoV-2 Antibody Test based on lateral flow method, approved by the NMPA on Feb 22 as the country's first POCT test for the SARS-CoV-2, can detect both IgM and IgG antibodies in human serum, plasma and whole blood samples within 15 minutes, effectively accelerating the on-site screening for suspected patients.
The other two antibody test products, Finecare SARS-CoV-2 Antibody Test and Finecare SARS-CoV-2 IgM Test, which use fluorescence immunochromatographic assay, are yet to be approved by the NMPA, but are even faster-they can detect either IgM antibody or both IgM and IgG antibodies within 10 minutes.
In addition, two antibody detection kits jointly developed by Wuhan Institute of Virology and a pharmaceutical company have started production and will soon be put into the market.
∙ Hangzhou JUST Biotherapeutics Co Ltd, for developing antibody and antibody-like biotherapeutics for the treatment of infectious disease.
∙ Chengdu ConMed Biosciences Inc, for developing new therapeutic antibody drugs using Hybridoma screening and cell line development platform.
Among the eight antibody drugs approved and available in the market last year, five were developed by companies based in Zhangjiang.
In May, Spevigo, a monoclonal antibody medication for treating rare skin diseases, filed for a new indication — the prevention of generalized pustular psoriasis.
At the exhibition hall, North China Pharmaceutical Group displayed Ormutivimab Injection, the first domestically produced rabies monoclonal antibody in China.
On April 12, Jiangsu province-based Chiatai Tianqing Pharmaceutical Group signed an agreement with Singaporean company Specialised Therapeutics, offering the latter the exclusive right to commercialize a new anti-PD1 antibody in Australia, New Zealand, Papua New Guinea and across Southeast Asia.
In March, Shanghai-based Junshi Biosciences granted commercialization rights of its monoclonal antibody in Southeast Asia to Excellmab, a joint venture of Rxilient Biotech.
China National Pharmaceutical Group Co Ltd, or Sinopharm, announced recently it had developed four Omicron-specific vaccine candidates, including inactivated, recombinant protein, and mRNA varieties, as well as an inhalable monoclonal antibody for COVID-19 prevention.
Currently, it is accelerating the introduction of innovative drugs to China and enhancing accessibility, which include a first-in-class antibody conjugate drug.
Small molecule drugs, new types of vaccines and new-generation antibody drugs will be the major sectors that Shanghai's biopharmaceutical companies will focus on in the near future, according to attendees of the IBIWS.
Wang Jingsong, founder, chairman and CEO of HBM, said the drug candidate is one of the company's representative innovative bispecific antibodies generated from its self-developed antibody development platform called HBICE and has significant potential value on a global basis.
A bispecific antibody is a molecule designed to recognize two different antigens or two different epitopes on the same antigen to treat tumors and other diseases and therefore is widely believed to have superior clinical therapeutic effects compared with traditional monoclonal antibodies.
Improved innovation, manufacturing savvy help domestic producers make inroads overseasThanks to much-improved research and development capabilities, Chinese companies able to quickly develop a myriad of nucleic acid, antigen and antibody test kits after the outbreak of COVID-19 have seen a spike in orders for the products in recent months.
A global leader in SHP2 inhibitor development, the company has finished phase-1 clinical study of an SHP2 inhibitor drug candidate and determined recommended doses of monotherapy and combination therapy with PD-1 antibody.
They include a PD-1 antibody for tumor immunotherapy, a tumor-targeting drug and a PARP inhibitor also used for cancer treatment.
I-Mab, a Shanghai-based biomedicine startup that has built an innovative and competitive pipeline mainly in oncology and autoimmune diseases since its founding in 2016, reached a strategic collaboration agreement with AbbVie from the US over I-Mab's CD47 antibody for next-phase R&D and global commercialization.
Independently operated by the BGI Health Ethiopia, the high-end laboratory provides passengers with RT-PCR and IgM antibody tests for COVID-19.
All these have been driving the country to move toward an early stage of innovation and engage more actively in original indication expansion, combo therapies and novel antibody work.
"As China deepens its understanding in areas such as oncology pathogenesis, biological mechanisms and antibody engineering, we expect this progress to continue.
Before he returned to his post after vacation, Tanvir had both PCR and antibody tests thrice and was quarantined for 14 days at the power plant.
In April, China's National Medical Products Administration approved the company's anti-PD-1 antibody tislelizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer, following the therapy's initial approval in classic Hodgkin's lymphoma in December 2019.
A recent case is I-Mab Biopharma's out-licensing deal with global drugmaker AbbVie Inc, for the rights of lemzoparlimab, an anti-CD47 monoclonal antibody developed by the Shanghai-based company to treat multiple forms of cancer.
The drug is a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric and esophageal cancers, among others, the company said.
The world's first healthy volunteer has been dosed in a phase-1 study of a SARS-CoV-2 neutralizing antibody.
It was also the first antibody of this kind to enter the clinical stage in China.
Shanghai-based biopharmaceutical company Junshi Biosciences announced on Sunday its SARS-CoV-2 neutralizing antibody, named JS016, has entered clinical trials at Huashan Hospital Affiliated to Fudan University.
Should phase-1 results show the antibody can be safely administered, the company intends to move to the next phase of testing to study the antibody’s ability to prevent and treat COVID-19.
”On April 28, the Ministry of Science and Technology issued a guideline on the emergency research and development of SARS-CoV-2 neutralizing antibody products, widely soliciting from society those with mature preclinical effectiveness, safety research foundation, high industrial conversion rate and ability to quickly enter clinical research.
The fully human monoclonal antibody was identified by screening blood samples of patients who recovered from COVID-19.
The China National Medical Products Administration announced on Saturday that the Chinese pharmaceutical company BeiGene Ltd's anti-PD-1 antibody tislelizumab had received its approval as a treatment for patients with classical Hodgkin's lymphoma who have received at least two prior therapies under priority review.
The exhibits will range from biological materials, biological enzymes, recombinant proteins, and blood products to new biological vaccines, therapeutic antibodies, transgenic mouse platforms, antibody technology service platforms, and data system development platforms, to help solve challenges facing pharmaceutical and biotechnological companies in product promotion, technological innovation, process optimization and industrial solutions, which will help accelerate the transformation and upgrading of the Chinese pharmaceutical industry, she said.
The two companies have agreed to jointly develop BeiGene's anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, the European Union, the United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan.
John V. Oyler, co-founder, CEO and chairman of BeiGene, said the company looks forward to working with Novartis to fulfill the global opportunity of the potentially differentiated anti-PD-1 antibody.
AI-based machine learning is useful in making predictive modeling for data analytics and rapid screening, as well as antibody testing, and AI machine learning will help develop vaccines and make them affordable and accessible, Zhang said.
China's biotechnology company BeiGene Ltd announced on Saturday that its anti-PD-1 antibody tislelizumab, an immunotherapy, had received approval from the China National Medical Products Administration as a treatment for patients with locally advanced or metastatic urothelial carcinoma (UC), the most common type of bladder cancer, following the therapy's initial approval in classical Hodgkin's lymphoma by the NMPA in December.